Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.38 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.36 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL970570 | 0.85 | ALDH1A1 (0.45) | TSHRHSD17B10KMT2AALDH1A1LMNA | |
| SCHEMBL969935 | 0.81 | APEX1 (0.44) | TSHRHSD17B10KMT2AALDH1A1LMNA | |
| SCHEMBL10594957 | 0.74 | PTGS1 (0.40) | PTGS1CXCR1CXCR2GSTP1GSTM2 | |
| SCHEMBL9627350 | 0.74 | PTGS1 (0.40) | PTGS1CXCR1CXCR2GSTP1GSTM2 | |
| SCHEMBL971410 | 0.73 | CCNB2 (0.54) | TSHRHSD17B10KMT2AALDH1A1LMNA | |
| SCHEMBL16724105 | 0.72 | SMN1; SMN2 (0.41) | PTGS1CXCR1CXCR2GSTP1GSTM2 | |
| SCHEMBL970611 | 0.70 | CA2 (0.38) | — | |
| SCHEMBL16724117 | 0.69 | CCNE1 (0.44) | PTGS1CXCR1CXCR2HSD17B10CCNE2 | |
| SCHEMBL21963005 | 0.69 | CCNE2 (0.44) | PTGS1CXCR1CXCR2GSTP1GSTM2 | |
| SCHEMBL9097022 | 0.68 | CA2 (0.45) | PTGS1CXCR1CXCR2HSD17B10CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2582706-A1 | 3-OXO-3,9-DIHYDRO-1H-CHROMENO[2,3-C]PYRROLES AS GLUCOKINASE ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-04-24 | — | — | EP | disclosed |
| US-8258134-B2 | Pyridazinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8178689-B2 | Tricyclic compounds | HOFFMAN-LA ROCHE INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110313002-A1 | TRICYCLIC COMPOUNDS | SARABU RAMAKANTH (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2011157682-A1 | 3-OXO-3,9-DIHYDRO-1H-CHROMENO[2,3-C]PYRROLES AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-22 | — | — | WO | disclosed |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HAYNES NANCY-ELLEN | 2011-01-27 | — | — | US | disclosed |
| EP-2268633-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-7741327-B2 | Pyrrolidinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127544-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | PTGS1 1120/4885CXCR1 4487/4885CXCR2 4535/4885 |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | GCKR, GCK, PDK2 | PTGS1 946/4885CXCR1 3801/4885CXCR2 3690/4885 |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | PTGS1 1120/4885CXCR1 4487/4885CXCR2 4535/4885 |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | GCK, GCKR, PDXK | PTGS1 1685/4885CXCR1 4675/4885CXCR2 4606/4885 |
| US-20110313002-A1 | TRICYCLIC COMPOUNDS | GPR119, PC, GOT2 | PTGS1 750/4885CXCR1 2889/4885CXCR2 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.